Risperidone - Janssen

Drug Profile

Risperidone - Janssen

Alternative Names: JNJ 410397 AAA; R 64766; R064766; Risperdal; Risperdal Consta; Risperdal Depot

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen L.P.
  • Developer Alkermes; Janssen; Janssen L.P.; Janssen Pharmaceutical KK; Janssen-Cilag; Xian-Janssen
  • Class Antineoplastics; Antipsychotics; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aggression; Autistic disorder; Bipolar disorders; Dementia; Schizophrenia
  • No development reported Anxiety disorders; Drug abuse; Major depressive disorder; Obsessive-compulsive disorders
  • Discontinued Gilles de la Tourette's syndrome

Most Recent Events

  • 28 Feb 2018 Xian Janssen withdraws a phase I bioequivalence trial prior to enrolment in healthy volunteers in China (NCT03220867)
  • 11 Dec 2017 Xian Janssen initiates enrolment in a phase I bioequivalence trial in healthy volunteers in China (NCT03220867)
  • 14 Jul 2017 Xian-Janssen plans a phase I bioequivalence trial in Healthy volunteers in China (PO) (NCT03220867)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top